Strikingly, while neither gefitinib nor WZB-117 given alone had an appreciable effect compared to the control treatment, their combination significantly inhibited the growth of the tumors (Figure 7A) without affecting the general health status of the mice as assessed by their body weight (Figure 7B), suggesting that GLUT1 inhibition successfully sensitized otherwise resistant NSCLC cells to gefitinib in vivo. This evidence concerns the gene SLC2A1 and non-small cell lung carcinoma.